Increase in angiotensin II type 1 receptor expression immediately after ischemia-reperfusion in isolated rat hearts

Circulation

Volumn 96, Issue 3, 1997, Pages 922-926

  Yang, B C ^a   Phillips, M I ^a   Ambuehl, P E J ^a   Shen, L P ^a   Mehta, P ^a   Mehta, J L ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Angiotensin; Ischemia; Myocardium; Reperfusion

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; BUFFER; LOSARTAN; RENIN;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; HEART DISEASE; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE PRESSURE; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

EID: 0030855268     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.96.3.922     Document Type: Article

References (35)

1. Cambien F, Poirier O, Lecerf L, Evans A, Cambou JP, Arveiler D, Luc G, Bard JM, Bara L, Ricard S, Tiret L, Amouyel P, Alhenc-Gelas F, Soubrier F. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature. 1992;359:641-644.
2. Raynolds MV, Bristow MR, Bush EW, Abraham WT, Lowes BD, Zisman LS, Taft CS, Perryman MB. Angiotensin-converting enzyme DD genotype in patients with ischemic or idiopathic dilated cardiomyopathy. Lancet. 1993;342:1073-1075.
3. Marian AJ, Yu QT, Workman R, Greve G, Roberts R. Angiotensin-converting enzyme polymorphism in hypertrophic cardiomyopathy and sudden cardiac death. Lancet. 1993;342:1085-1086.
4. Ohishi M, Fuji K, Minamino T, Higaki J, Kamitani A, Rakugi H, Zhao Y, Mikami H, Miki T, Ogihara T. A potent genetic risk factor for restenosis. Nat Genet. 1993;5:324-325.
5. Alderman MH, Madhavan S, Ooi WL, Cohen H, Sealey JE, Laragh JH. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med. 1991;324:1098-1104.
6. Fleetwood G, Boutinet S, Meier M, Wood JM. Involvement of the renin-angiotensin system in ischemic damage and reperfusion arrhythmias in the isolated perfused rat heart. J Cardiovasc Pharmacol. 1991;17:351-356.
7. Dzau VJ. Cell biology and genetics of angiotensin in cardiovascular disease. J Hypertens. 1994;12(suppl):S3-S10.
8. Vaughan DE, Declerck PJ, Vanhoutte P, De Mol M, Collen D. Reactivated recombinant plasminogen activator inhibitor-1 (rPAI-1) effectively prevents thrombolysis in vivo. Thromb Haemost. 1992;68:60-63.
9. Rydzewski B, Zelezna B, Tang W, Sumners C, Raizada MK. Angiotensin II stimulation of plasminogen activator inhibitor-1 gene expression in astroglial cells from the brain. Endocrinology. 1992; 130:1255-1262.
10. Werrmann JG, Cohen SM. Comparison of the effects of angiotensin converting enzyme inhibition with those of angiotensin II receptor antagonism on functional and metabolic recovery in the post-ischemic working rat heart as studied by 31P nuclear magnetic resonance. J Cardiovasc Pharmacol. 1994;24:573-586.
11. Yoshiyama M, Kim S, Yamagishi H, Omura T, Tant T, Yanagi S, Toda I, Teragaki M, Akioka K, Takeuchi K, Takeda T. Cardioprotective effect of the angiotensin II type 1 receptor antagonist TCV-116 on ischemia-reperfusion injury. Am Heart J. 1994;128:1-6.
12. Pfeffer M, Braunwald E, Boye L, the SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1992;327: 669-677.
13. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992;327:685-691.
14. Sechi LA, Griffin CA, Grady EF, Kalinyak JE, Schambelan M. Characterization of angiotensin II receptor subtypes in rat heart. Circ Res. 1992;71:1482-1489.
15. Allen AM, Yamada H, Mendelsohn FA. In vitro autoradiographic localization of binding to angiotensin receptor in the heart. Int J Cardiol. 1990;28:25-33.
16. Sun Y, Weber KT. Angiotensin II and aldosterone receptor binding in rat heart and kidney: response to chronic angiotensin II or aldosterone administration. J Lab Clin Invest. 1993;122:404-411.
17. Feolde E, Vigne P, Frelin C. Angiotensin II receptor subtypes and biological response in the rat heart. J Mol Cell Cardiol 1993;25: 1359-1367.
18. Sun Y, Weber KT. Angiotensin II receptor binding following myocardial infarction in the rat. Cardiovasc Res. 1994;28:1623-1628.
19. Yang BC, Virmani R, Nichols WW, Mehta JL. Platelets protect against myocardial dysfunction and injury induced by ischemia and reperfusion in isolated rat hearts. Circ Res. 1993;72:1181-1190.
20. Neely TR, Rovetto MJ. Techniques for perfusing isolated rat hearts. Methods Enzymol. 1975;39:43-60.
21. Wielbo D, Sernia C, Gyurko R, Phillips MI. Antisense inhibition of hypertension in the spontaneously hypertensive rat. Hypertension. 1995;25:314-319.
22. Scholkens BA, Linz W, Lindpaintner K, Ganten D. Angiotensin deteriorates but bradykinin improves cardiac function following ischemia in isolated rat hearts. J Hypertens. 1987;5(suppl 5):S7-S9.
23. Samani NJ, Morgan K, Brammar WJ, Swales JD. Detection of renin messenger RNA in rat tissues: increased sensitivity using an RNAse protection technique. J Hypertens. 1987;5(suppl 2):S19-S21.
24. Campbell DJ, Habener JF. Angiotensinogen gene is expressed and differentially regulated in multiple tissues of the rat. J Clin Invest. 1986;78:31-39.
25. Dzau VJ, Mukoyama M, Pratt RE. Molecular biology of angiotensin receptors: target for drug research? J Hypertens 1994;12(suppl 2):S1-S5.
26. Geisterfer AAT, Peach MJ, Owens GK. Angiotensin II induces hypertrophy, not hyperplasia, of cultured rat aortic smooth muscle cells. Circ Res. 1988;62:749-756.
27. Itoh H, Pratt RE, Dzau VJ. Atrial natriuretic factor inhibits hypertrophy of vascular smooth muscle cells. J Clin Invest. 1990;86: 1690-1697.
28. Naftilan AJ, Pratt RE, Dzau VJ. Induction of PDGF A-chain and c-myc gene expression by angiotensin II in cultured vascular smooth muscle cells. J Clin Invest. 1989;83:1419-1424.
29. Itoh H, Mukoyama M, Pratt RE, Gibbons GH, Dzau VJ. Multiple autocrine growth factors modulate vascular smooth muscle cell response to angiotensin II. J Clin Invest. 1993;91:2268-2274.
30. Deng H, Guo H, Qian X. Clinical significance of fibrinolytic system defectiveness in exercise induced myocardial ischemia and its mechanism. Chung Hua Nei Ko Tsa Chih. 1995;34:305-308.
31. 2-adrenergic receptors in human failing hearts: evaluation of the absolute cardiac mRNA levels by two independent methods. J Mol Cell Cardiol. 1996;28:1-10.
32. Van Gilst WH, deGraeft PA, Wesseling H, deLangen CDJ. Reduction of reperfusion arrhythmias in the ischemic isolated rat heart by angiotensin converting enzyme inhibitors: a comparison of captopril. enalapril and HOE 498. J Cardiovasc Pharmacol. 1986;8: 722-728.
33. Ribuot C, Rochette E. Converting enzyme inhibitors (captopril, enalapril, perindopril) prevent early post infarction ventricular fibrillation in the anaesthetized rat. Cardiovasc Drugs Ther. 1987;1: 51-55.
34. Cleland JGF, Dargie HJ, Ball SG, Gillen G, Hodsman GP, Morton JJ, East BW, Robertson I, Ford I, Robertson JI. Effects of enalapril in heart failure: a double blind study of effects on exercise performance renal function hormones and metabolic state. Br Heart J. 1985;54:305-312.
35. Ribuot C, Yamaguchi N, Godin D, Jette L, Nadeau R. Intracoronary administration of saralasin: effects on cardiac arrhythmias induced by ischemia and reperfusion in the anaesthetised dog. Cardiovasc Res. 1992;26:968-972.